Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Nonalcoholic Steatohepatitis

In brief

The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.

Key facts

Study ID
NCT03053050
Run by
Gilead Sciences
People needed
808
Starts
2017-02-13
Expected to finish
2019-06-19
Last updated by the study team
2020-06-29

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.